Follistatin vs Palmitoyl Tripeptide-1
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Follistatin
Follistatin is a glycoprotein that inhibits myostatin, the protein responsible for limiting muscle growth. By blocking myostatin, follistatin can theoretically allow for increased muscle development beyond natural limits.
Full details →Palmitoyl Tripeptide-1
Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide that stimulates collagen production. It's one of two peptides in the Matrixyl 3000 complex, working synergistically with Palmitoyl Tetrapeptide-7.
Full details →Side-by-Side Comparison
| Aspect | Follistatin | Palmitoyl Tripeptide-1 |
|---|---|---|
| Mechanism | Binds to and neutralizes myostatin and activin, both of which are negative regulators of muscle mass. This removes the natural brake on muscle growth, allowing for enhanced hypertrophy. | Mimics the skin's own mechanism for producing collagen by acting as a messenger peptide that signals fibroblasts to produce more collagen and other extracellular matrix components. |
| Typical Dosage | Research protocols typically use 100-300mcg daily, though optimal dosing is not well established. Gene therapy approaches have also been studied. | Topical: Typically 2-4% in serums, often combined with Palmitoyl Tetrapeptide-7 as Matrixyl 3000. |
| Administration | Subcutaneous injection. Different isoforms exist (FS344, FS315) with varying properties. Requires careful sourcing due to complexity. | Topical application 1-2 times daily. The palmitoyl group enhances skin penetration compared to non-lipidated versions. |
| Side Effects | Limited human data. Theoretical concerns about effects on other organs where activin signaling is important. | Very well-tolerated. Suitable for most skin types including sensitive skin. |
| Best For |